ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Nevada » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Nevada

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
CHRIS CARAANG M.D.

Cardiovascular Disease

10,667

$400K

951
900 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 24%

$38
Average prescription price

Avg: $64

CRES MIRANDA MD

Cardiovascular Disease

9,078

$1.31M

600
496 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 24%

$145
Average prescription price

Avg: $64

CARLOS FONTE M.D.

Cardiovascular Disease

8,479

$379K

697
636 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 24%

$45
Average prescription price

Avg: $64

SHADI DAOUD M.D.

Cardiovascular Disease

7,743

$234K

683
617 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 24%

$30
Average prescription price

Avg: $64

SVETLANA BARBARASH MD

Cardiovascular Disease

7,051

$285K

622
569 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 24%

$40
Average prescription price

Avg: $64

CHARLES RUGGEROLI MD

Cardiovascular Disease

6,905

$376K

383
329 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 24%

$54
Average prescription price

Avg: $64

GEORGE FARAH MD

Cardiovascular Disease

6,438

$258K

706
656 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 24%

$40
Average prescription price

Avg: $64

JERRY ROUTH MD

Cardiovascular Disease

6,400

$462K

716
640 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 24%

$72
Average prescription price

Avg: $64

THOMAS LAMBERT MD

Cardiovascular Disease

6,013

$340K

514
469 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 24%

$57
Average prescription price

Avg: $64

KENNETH SHAH M.D.

Cardiovascular Disease

5,265

$435K

277
226 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 24%

$83
Average prescription price

Avg: $64

KESHAV CHANDER MD

Cardiovascular Disease

5,255

$160K

528
488 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

12%
prescriptions for brand name drugs

Avg: 24%

$31
Average prescription price

Avg: $64

JOHN WILLIAMSON M.D.

Cardiovascular Disease

5,224

$278K

421
390 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 24%

$53
Average prescription price

Avg: $64

JOSEPH STEVENSON D.O.

Cardiovascular Disease

5,034

$2.25M

454
390 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 24%

$447
Average prescription price

Avg: $64

THOMAS DAVEE M.D.

Cardiovascular Disease

4,981

$189K

453
426 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 24%

$38
Average prescription price

Avg: $64

LARRY NOBLE M.D.

Cardiovascular Disease

4,731

$192K

393
371 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 24%

$41
Average prescription price

Avg: $64

WILLIAM FLIGNOR MD

Cardiovascular Disease

4,603

$207K

354
259 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

11%
prescriptions for brand name drugs

Avg: 24%

$45
Average prescription price

Avg: $64

RONALD ROTH MD

Cardiovascular Disease

4,593

$354K

285
255 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 24%

$77
Average prescription price

Avg: $64

FOAD MOAZEZ M.D.

Cardiovascular Disease

4,543

$251K

446
413 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 24%

$55
Average prescription price

Avg: $64

PAUL HEEREN MD

Cardiovascular Disease

4,474

$269K

447
418 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 24%

$60
Average prescription price

Avg: $64

STANLEY THOMPSON M.D.

Cardiovascular Disease

4,465

$245K

379
355 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 24%

$55
Average prescription price

Avg: $64

CARL JUNEAU M.D.

Cardiovascular Disease

4,439

$329K

403
376 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 24%

$74
Average prescription price

Avg: $64

STEPHEN SAVRAN MD

Cardiovascular Disease

4,347

$303K

524
465 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 24%

$70
Average prescription price

Avg: $64

DAVID BAKER MD

Cardiovascular Disease

4,281

$234K

516
469 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 24%

$55
Average prescription price

Avg: $64

FRANCIS KELLEY M.D.

Cardiovascular Disease

4,173

$196K

406
345 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 24%

$47
Average prescription price

Avg: $64

BASIL CHRYSSOS M.D.

Cardiovascular Disease

4,048

$201K

408
374 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 24%

$50
Average prescription price

Avg: $64

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank